Cytosorbents Corporation
Every calculator, already run for CTSO
Open the full toolkit →You have the numbers on CTSO. Get the argument.
A written report on which of these readings actually decide the outcome for Cytosorbents Corporation, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
1 analysts covering CTSOAnalyst Price Target Disagreement for Cytosorbents Corporation
Wall Street's bull case implies +1920% from the current price; the bear case implies +279%. A 1641% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for CTSO
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Cytosorbents Corporation
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to…
CTSO — frequently asked
Is CTSO a buy right now?
Wall Street's consensus rating on Cytosorbents Corporation is none across 1 analysts, with a mean price target of $47.50 (+1099% vs. the current $3.96). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is CTSO's next earnings date?
Cytosorbents Corporation is next scheduled to report earnings around Nov 12, 2026. A full CTSO research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Cytosorbents Corporation?
Analysts covering Cytosorbents Corporation (CTSO) range from a bear-case target of $15.00 to a bull-case high of $80.00, with a mean consensus target of $47.50 across 2 analysts. The spread of $65.00 (1641% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Cytosorbents Corporation against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Cytosorbents Corporation
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CTSO research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Cytosorbents Corporation, in minutes. 3 free reports included with every account — no credit card required.